12-Nov-2025 3:05 PM CST - Business Wire Adagio Medical Reports Third Quarter 2025 Results Adagio Medical Holdings, Inc (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of app
5-Nov-2025 7:00 AM CST - Business Wire Adagio Medical to Present at the Piper Sandler 37th Annual Healthcare Conference Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 10:30 a.m. ET at the Lotte Palace in New York, NY. Presentation Information A live and recorded webcast of the presentation will be available at: htt
13-Aug-2025 3:30 PM CST - Business Wire Adagio Medical Reports Second Quarter 2025 Results Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Surpassed 85% enrollment in the FULCRUM-VT pivotal study of the Companys vCLAS Cryoablation System. The study, which seeks to enroll 206 patients with either ischemic or non-ischemic
15-May-2025 3:05 PM CST - Business Wire Adagio Medical Reports First Quarter 2025 Results Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the first quarter ended March 31, 2025. Recent Business Highlights: Received Breakthrough Device Designation from the U.S. Food and Drug Administration (the FDA) for the vCLAS Cryoablation System (vCLAS), for the treatment of drug-refractory, recu
7-May-2025 7:30 AM CST - Business Wire Adagio Medical to Present at the BofA Securities 2025 Health Care Conference Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the BofA Securities Health Care Conference on Tuesday, May 13, 2025, at 9:20 a.m. PT at the Encore Hotel in Las Vegas, NV. Presentation Information A live and recorded webcast of the presentation will be available at: https://bofa.verac
31-Mar-2025 7:30 AM CST - Business Wire Adagio Medical Reports Fourth Quarter and Full Year 2024 Results Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights: Reported total company revenue of $137 thousand in the fourth quarter of 2024, compared to $78 thousand in the fourth quarter of 2023. Full year revenue for 2024 was $0.6 million compared to $0.3
12-Nov-2025 3:05 PM CST - Business Wire Adagio Medical Reports Third Quarter 2025 Results Adagio Medical Holdings, Inc (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of app
5-Nov-2025 7:00 AM CST - Business Wire Adagio Medical to Present at the Piper Sandler 37th Annual Healthcare Conference Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 10:30 a.m. ET at the Lotte Palace in New York, NY. Presentation Information A live and recorded webcast of the presentation will be available at: htt
13-Aug-2025 3:30 PM CST - Business Wire Adagio Medical Reports Second Quarter 2025 Results Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the second quarter ended June 30, 2025. Recent Business Highlights: Surpassed 85% enrollment in the FULCRUM-VT pivotal study of the Companys vCLAS Cryoablation System. The study, which seeks to enroll 206 patients with either ischemic or non-ischemic
15-May-2025 3:05 PM CST - Business Wire Adagio Medical Reports First Quarter 2025 Results Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the first quarter ended March 31, 2025. Recent Business Highlights: Received Breakthrough Device Designation from the U.S. Food and Drug Administration (the FDA) for the vCLAS Cryoablation System (vCLAS), for the treatment of drug-refractory, recu
7-May-2025 7:30 AM CST - Business Wire Adagio Medical to Present at the BofA Securities 2025 Health Care Conference Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (Adagio or the Company), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the BofA Securities Health Care Conference on Tuesday, May 13, 2025, at 9:20 a.m. PT at the Encore Hotel in Las Vegas, NV. Presentation Information A live and recorded webcast of the presentation will be available at: https://bofa.verac
31-Mar-2025 7:30 AM CST - Business Wire Adagio Medical Reports Fourth Quarter and Full Year 2024 Results Adagio Medical Holdings, Inc. (Nasdaq: ADGM), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights: Reported total company revenue of $137 thousand in the fourth quarter of 2024, compared to $78 thousand in the fourth quarter of 2023. Full year revenue for 2024 was $0.6 million compared to $0.3
